NGF and early-onset autosomal dominant Alzheimer disease: Since NGF does not cross the blood brain barrier, NGF administration through intracerebroventricular (ICV) route has been carried out to evaluate the safety and efficacy of NGF in Alzheimer's disease patients [2].